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Abstract
Background: Delay in diagnosis of cancer may worsen prognosis. The aim of this study is to explore patient-,
general practitioner (GP)- and system-related delay in the interval from first cancer symptom to diagnosis and
treatment, and to analyse the extent to which delays differ by cancer type.
Methods: Population-based cohort study conducted in 2004-05 in the County of Aarhus, Denmark (640,000
inhabitants). Data were collected from administrative registries and questionnaires completed by GPs on 2,212
cancer patients newly diagnosed during a 1-year period. Median delay (in days) with interquartile interval (IQI) was
the main outcome measure.
Results: Median total delay was 98 days (IQI 57-168). Most of the total delay stemmed from patient (median 21
days (7-56)) and system delay (median 55 days (32-93)). Median GP delay was 0 (0-2) days. Total delay was shortest
among patients with ovarian (median 60 days (45-112)) and breast cancer (median 65 days (39-106)) and longest
among patients with prostate (median 130 days (89-254)) and bladder cancer (median 134 days (93-181)).
Conclusion: System delay accounted for a substantial part of the total delay experienced by cancer patients. This
points to a need for shortening clinical pathways if possible. A long patient delay calls for research into patient
awareness of cancer. For all delay components, special focus should be given to the 4
th quartile of patients with
the longest time intervals and we need research into the quality of the diagnostic work-up process. We found
large variations in delay for different types of cancer. Improvements should therefore target both the population at
large and the specific needs associated with individual cancer types and their symptoms.
Background
The time interval from first symptom to start of treatment
(i.e. surgery, chemotherapy) is often labelled delay even if
parts of this delay are unavoidable. Delay in cancer diagno-
sis is common and long delay is associated with significant
mental strain and possibly a worsened prognosis [1-3].
Although the exact effect of delay on clinical outcomes
remains unclear and varies between cancers, it is generally
accepted that total delay should be as short as possible
[4-11]. British studies attribute that long delay may
account for 5-10,000 extra deaths in the UK [2,12]. Only a
few studies have analyzed in detail how delay is related to
patients’ health-seeking behaviour, general practitioners’
(GPs’) clinical performance and system-related factors
such as logistics, waits and administrative procedures.
Moreover, previous studies have covered only one or few
specific cancer types [13-18]. Cancer represents one of the
most severe diseases requiring the concerted effort of the
entire care system. It is therefore an excellent candidate
for a study of the interplay between the elements forming
part of the overall clinical pathway. Knowledge of this may
enable targeted efforts to improve the organization of care.
The aim of this study was to conduct a population-based
cohort study examining patient-, GP- and system-related
delay and the extent to which delays vary by cancer type.
Methods
Study design
We performed a cohort study in the Danish County of
Aarhus, which has 640,000 inhabitants, approx. 3,000
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mark’s publicly funded health-care system provides free
access to primary care and outpatient and hospital care
(Figure 1). More than 98% of the Danish citizens are
registered with a GP [19,20]. GPs function as gatekeepers
to the rest of the health-care system, carrying out initial
diagnostic investigations including referral to initial x-ray
and endoscopic procedures When indicated, they refer
patients to hospitals or outpatient clinics, thus delegating
further responsibility to secondary care. Danish GPs are
required to keep detailed electronic records.
We included all newly diagnosed cancer patients dur-
ing the 1-year period from 1 September 2004 to 31
August 2005. Patients younger than 18 years and patients
with non-melanoma skin cancers were excluded. Patients
were enrolled based on computerised data from the
county hospital discharge registry (HDR), which for each
hospital admission and outpatient visit records the
patient’s civil registration number (CRN), dates of admis-
sion and discharge, surgical procedure(s) performed and
discharge diagnoses classified according to the interna-
tional classification of diseases (ICD-10). We included all
patients listed in the registry during the study period
with incident cancer diagnoses, i.e. we excluded those
with a recurrent cancer. Patients with previous cancer,
but of another type, were regarded as incident cases. We
then linked the HDR data to the county’s Health Service
Registry (HSR) in order to identify each patient’s GP. The
personal identifier used to link records to individuals
across Danish registries is the CRN, which is assigned to
all Danish citizens [21].
Ethics approval
According to the Scientific Ethics Committee in the
County of Aarhus, the project did not need approval by
the Danish Biomedical Research Ethics Committee
System. The study was approved by the Danish Data Pro-
tection Agency and the Danish National Board of Health.
Data collection
A questionnaire was sent to the GP of each patient identi-
fied in the HDR. The GP was asked to confirm the diagno-
sis and to give a detailed description of the patient’s
diagnostic pathway using the dates reported in the medical
record and the mandatory discharge letters from hospitals
and specialists which report the date of first admission,
the date of diagnosis and of first treatment. Furthermore,
the GP provided the dates of the first patient symptoms
(adherent to the actual cancer disease) as reported to the
GP by the patient, the first presentation to the GP/prac-
tice, the initiation of diagnostic procedures, hospital refer-
ral, the first hospital visit, the diagnosis and the treatment
start. Non-responders received a reminder after three
weeks. The questionnaire was pilot-tested by the scientific
staff and lay persons at the Department and Research Unit
for General Practice, Aarhus and by 40 GPs from Vejle
County, Denmark (purposefully selected by gender, age
and practice location) [22].
Outcome measures
In accordance with most other research we used the
term delay when calculating the different time intervals
from first symptom to treatment start. Delay was
- Denmark has a tax-financed health care system with free access to 
medical advice and treatment in general practices and hospitals.  
- All GPs in Denmark are independent contractors with the public 
health service and are remunerated on a mixed fee for service and 
capitation basis. 
- Almost all (98%) citizens are listed with a particular general 
practice which they have to consult for advice and treatment. The 
practice list size is on average 1,550 patients per GP (including 
children).  
- GPs act as gatekeepers to investigations and hospital referrals.  
Figure 1 The Danish health care system.
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by the GPs. Delay was divided into three delay stages.
(1) Patient delay: Time from first perceived patient
symptom until first presentation to the GP; (2) GP
delay: Period from first presentation until initiation of
an investigation of potentially cancer-related symptoms,
i.e. biopsy, referral to imaging diagnostic, endoscopy or
to other health-care professionals; (3) System delay:
Time from the start of the GP-initiated investigation
until the start of treatment. System delay was further
divided into delay encountered in the primary health
care sector (GP retaining responsibility for the patient)
and in the secondary health care sector (the patient is
no longer the responsibility of the GP) (Figure 2). Sys-
tem delay was defined in this way to be able to analyse
to which extent cancer was seen and acted upon as an
acute disease. In addition, total delay was defined as the
interval from the first perceived patient symptom until
treatment start.
We first computed delay for all cancer types and then for
the 10 most frequent cancers found among the patients.
The delay data are presented as medians and interquartile
intervals (IQIs). The Wilcoxon rank-sum test was used to
compare delay for those patients whose GPs were involved
in the diagnostic investigation and those whose GPs were
not. A P-value of 0.05 or less was used to signify statistical
significance. Data were analysed using Stata software,
version 11 (StataCorp, College Station, Tex).
Results
Descriptive data
A total of 2,212 questionnaires were completed. A total
of 467 out of 543 physicians from 255 general practices
participated in the study. On average, they filled in ques-
tionnaires on 4.7 patients (range 1-15, median 4). The
physician response rate was 83% (Figure 3). No signifi-
cant differences were found between the participating
and non-participating physicians concerning gender,
practice organization and years since graduation. GPs
were involved in the diagnostic pathway in 1,892 (86%) of
the 2,212 cancer cases. For the remaining 320 cancer
cases, we could only calculate system delay in the second-
ary health-care sector because they were admitted
directly to the hospital by out-of-hours or accident and
emergency services (A&E), often for acute-onset symp-
toms. Table 1 shows the distribution of the 10 most fre-
quent cancers diagnosed in Denmark [23] compared with
the cancer distribution by type in our study.
Delay data
Table 2 shows the different delay stages for all cancers and
for the 10 most frequent cancers diagnosed among study
patients. Overall, among patients with complete question-
naire data the median total delay was 98 days (IQI 57 to
168), the median patient delay was 21 days (IQI 7 to 56),
the median GP delay was 0 days (IQI 0 to 2) and the med-
ian system delay was 55 days (IQI 32 to 93). The period
System delay in 
primary health care 
First 
symptom 
First contact 
with the GP 
Referral to 
hospital 
Initiation of 
investigation of 
cancer  -  related 
symptoms 
First in  - 
hospital visit 
Diagnosis/
referral to 
treatment 
Initiation of 
treatment 
Treatment delay 
System delay  GPdelay  Patient delay 
Delay in primary health care  Delay in secondary health care 
Diagnostic delay in 
secondary health care 
Total delay 
Figure 2 Subdivision of delay.
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health care) accounted for most of the system delay (med-
ian 46 days, IQI 26 to 78), while system delay in primary
health care was minimal (median 0 days, IQI 0 to 12).
Patients who saw their GPs prior to diagnosis experienced
a statistically significantly (Z = 3.257, P = 0.001) longer
system delay in secondary health care (median 46 days,
IQI 26 to 78) than those who were admitted directly to
the hospital (median 37 days, IQI 17 to 63).
The shortest total delay was seen among patients with
ovarian cancer (median 60 days, IQI 45 to 112); the sec-
ond shortest delay was seen among patients with breast
cancer (median 65 days, IQI 39 to 106). The longest total
delay was found among patients with prostate (median
130, IQI 89 to 254) and bladder cancer (median 134, IQI
93 to 181) (Table 2). As shown in Figure 4, the 4
th quar-
tile of patients experienced long patient, GP, system and
total delay. Non-response analysis revealed no major dif-
ferences between participating and non-participating
physicians in terms of their cancer patients’ age, gender
or distribution of cancer diagnoses.
Discussion
We identified a median total delay of 98 days and a total
delay exceeding 168 days among ¼ of the patients. Patient
and system delay accounted for most of the total delay.
Even if the median GP delay was 0 days, a considerable
proportion of the patients experienced a long GP-related
delay. We found much variation in delay by cancer type.
As expected, patients who saw their GPs prior to diagnosis
Newly diagnosed cancer patients
(3,138 fulfilled inclusion criteria)
Questionnaires answered (2,212) 
Response rate: 2,212/2,663=83%
134 cancer cases excluded: GP 
refused to participate (83), GP 
unable to answer (51)
Cancer cases eligible for inclusion 
before GP confirmed diagnosis
(3,091) 
47 cancer cases excluded 
(Health Service Registry): 
Patient not listed with a GP (47)
Cancer cases eligible for inclusion 
after GP confirmed diagnosis
(2,663) 
428 cancer cases excluded by 
GPs due to errors in registry 
information: Date of diagnosis 
before or after inclusion period 
(380), misdiagnosis (48)
317 questionnaires not answered
Figure 3 Flowchart.
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list care directly.
In this paper we alternate between the terms “delay” and
“time interval”. Strictly speaking, the use of the term
“delay” is often inappropriate as part of the time interval is
unavoidable, and therefore the term “time interval” is
often more correct. As delay is still widely used in the
literature we have for comparable reasons continued to
use this term, but future investigations might more conse-
quently change the term to time interval.
The study covered the entire population above 17 years
with newly diagnosed cancer in a large catchment area
counting more than 600,000 inhabitants. The study is thus
based on data on the total health-care performance in
relation to cancer within a region during a 1-year period.
We reduced selection bias by using registry information
to identify potential study participants independently of
the participating GPs and hospital physicians. The excel-
lent response rate (83%) limits a possible selection bias;
but, still, non-responding GPs may have seen patients with
special diagnostic pathways, although non-response analy-
sis revealed no major differences between participating
and non-participating physicians in terms of their cancer
patients’ age, gender or distribution of cancer diagnoses.
The description of socioeconomic patient characteristics
associated with delay was not within the scope of this arti-
cle, but this issue is covered in another article [24].
We further assured that only eligible patients were
included by requesting that their GPs confirmed their
diagnoses. Given the uniform organisation of health care
throughout Denmark, we consider our results representa-
tive of the country as a whole. We cannot determine
whether our findings are representative of other cultural
settings or health-care systems in other counties. We
recognize that the sample sizes of some of the delay calcu-
lations (especially total delay) for 6 of the 10 cancer types
in the study (Table 2) are small (due to missing data and a
small number of these cancers in Denmark). This may
have affected the IQIs and evidently the generalisability of
the results.
Minimisation of recall bias is a key prerequisite for the
validity of our findings. We therefore encouraged the
GPs to consult their electronic patient files including the
discharge letters when filling in the questionnaires. Still,
lack of complete information in some questionnaires may
have introduced information bias. We anticipate that this
bias tends to underestimate the reported delay, which
may especially be the case for GP-reported delay. In
another paper we have shown that it is difficult to define
the time of symptom onset [25]. However, we do not yet
know whether the patients’ or the GPs’ estimates are the
most correct ones.
Comparison of findings with previous literature
Seen from a health services planning and a research and
population perspective, it is relevant to include all can-
cers to be able to formulate a hypothesis about the need
to focus on patient awareness of symptoms and access to
diagnostic work-up of serious disease. However, our data
on the specific cancer types also emphasise the need for
detailed analyses of each specific cancer. We also need
more research on the influence of symptom presentation
in relation to delay [26]. A previous survey from the
same region by Bjerager [13] showed that most delay in
diagnosing lung cancer was attributable to system delay,
which is consistent with our findings.
Our total delay findings accord with those of Allgar and
Neal [17] who investigated patient-reported delay for six
cancer types in a large population of UK cancer patients.
However, in contrast to our results, they found that the
main problem was patient and primary care delay. This
discrepancy may be attributed to differences in the Eng-
lish and Danish health care systems in terms of culture,
organisation and capacity, and to differences in study
design and definitions of delay stages. Our broad defini-
tion of system delay encompassed not only time to
Table 1 The number and the distribution of the 10 most frequent cancers diagnosed in Denmark and the cancer
distribution by type in the study
Cancers in DK (N = 33501 in 2003)* Cancers in this study (N = 2212)
1. Breast cancer (4027 - 12.0%) 1. Lung cancer (328 - 14.8%)
2. Colorectal cancer (3576 - 10.7%) 2. Breast cancer (311 - 14.1%)
3. Lung cancer (3500 - 10.4%) 3. Colorectal cancer (291 - 13.2%)
4. Prostate cancer (2378 - 7.1%) 4. Prostate cancer (214 - 9.7%)
5. Bladder cancer (1710 - 5.1%) 5. Melanoma (131 - 5.9%)
6. Melanoma (1222 - 3.6%) 6. Bladder cancer (80 - 3.6%)
7. CNS cancer (898 - 2.7%) 7. Non-Hodgkin’s lymphoma (65 - 2.9%)
8. Non-Hodgkin’s lymphoma (828 - 2.5%) 8. Pancreas cancer (63 - 2.8%)
9. Pancreas cancer (700 - 2.1%) 9. Ovarian cancer (59 - 2.7%)
10. Leukaemia (694 - 2.1%) 10. Corpus uteri cancer (47 - 2.1%)
* Including cancers in patients younger than 18 years
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Page 5 of 8Table 2 Delay (in days) for all and the 10 most frequent cancers in the study when the GP was involved in the diagnostic investigation process
System delay
Total delay Patient delay GP delay System delay in secondary health care System delay in
secondary health
care (GP not
involved)
Total system
delay
System delay in
primary health
care
System delay in
secondary health
care
Diagnostic delay
in secondary
health care
Treatment delay
Cancer type (Cancer
cases, GP involved/Cancer
cases, GP not involved)
N Median IQI* N Median IQI N Median IQI N Median IQI N Median IQI N Median IQI N Median IQI N Median IQI N Median IQI
All cancers (1892/320) 936 98 57-
168
1237 21 7-
56
1877 0 0-
2
1422 55 32-
93
1874 0 0-
12
1412 46 26-
78
1823 29 14-
57
1403 14 0-
28
174 37 17-
63
Breast cancer (291/20) 159 65 39-
106
168 14 0-
56
289 0 0-
0
269 40 25-
59
287 0 0-
0
268 37 22-
51
281 21 13-
36
266 12 4-
20
10 29 23-
38
Colorectal cancer (254/37) 159 109 65-
194
187 28 14-
56
254 0 0-
6
212 56 34-
87
254 0 0-
10
216 48 28-
71
251 30 15-
50
215 14 0-
28
24 15 3-
30
Lung cancer (253/75) 128 108 82-
167
182 28 7-
56
251 0 0-
9
182 69 47-
96
250 7 0-
18
181 55 36-
79
246 27 14-
46
182 23 8-
36
40 51 27-
76
Prostate cancer (190/24) 73 130 89-
254
110 28 0-
112
186 0 0-
6
117 102 55-
151
187 6 0-
18
115 75 44-
135
183 80 44-
110
114 9 0-
29
16 83 48-
139
Melanoma (122/9) 38 114 79-
279
40 70 28-
196
122 0 0-
0
114 39 22-
65
122 0 0-
15
112 27 15-
54
117 20 0-
42
110 13 0-
23
14 9
Bladder cancer (73/7) 32 134 93-
181
52 14 0-
28
72 0 0-
10
43 91 52-
119
71 2 0-
19
42 80 45-
113
68 62 35-
87
43 0 0-
20
4 51 22-
75
Non-Hodgkin’s lymphoma
(54/11)
29 78 58-
118
43 21 7-
42
53 0 0-
3
34 60 44-
86
54 2 0-
14
34 55 39-
73
51 36 14-
68
34 12 5-
29
4 38 33-
51
Pancreas cancer (54/9) 21 87 49-
153
40 14 7-
42
53 0 0-
6
28 63 27-
117
54 0 0-
15
28 59 25-
91
51 27 11-
68
27 14 0-
41
5 15 10-
50
Ovarian cancer (47/12) 32 60 45-
112
38 21 0-
35
47 0 0-
2
40 30 21-
49
47 0 0-
8
40 26 20-
43
45 21 12-
31
39 1 0-
21
9 40 20-
62
Corpus uteri cancer (41/6) 35 99 51-
22
35 21 0-
140
41 0 0-
0
41 64 41-
106
41 0 0-
1
41 60 32-
101
39 38 23-
79
39 7 0-
14
3 59 28-
77
Others (513/110) 233 96 56-
178
342 21 7-
56
509 0 0-
6
338 63 35-
110
507 0 0-
11
335 52 29-
93
491 27 12-
55
334 17 0-
34
58 32 13-
62
N in each column is the number of answers with complete data. Last column shows system delay in secondary health care when the GP was not involved in the diagnostic investigation process
*IQI = interquartile intervaldiagnosis, but the time to start of treatment, as we
expected a significant delay between diagnosis and treat-
ment initiation. We need an internationally agreed defini-
tion on delay stages (Figure 2); a task that has been
initiated in the UK National Initiative on Early Diagnosis
of Cancer (NAEDI) and in the Cancer and Primary Care
Research International Network (CA-PRI) [2,27].
Implications of the study
Cancer is a serious disease. The diagnostic evaluation is
complex and often conducted in a sequential process,
which may explain the long system delay. However,
another explanation may be that Danish cancer patients
have to wait longer for basic diagnostic investigations.
Thus, another main finding of the present study was the
long patient delay. We lack international knowledge
about variation in patient awareness of symptoms and
differences in delay and about the interaction between
the health care structure and patient delay [28-30].
A recent paper showed that delay in diagnosis may
have severe prognostic consequences and may partly
explain the bad cancer outcome results in countries like
the UK and Denmark [12]. Recent years have therefore
seen the introduction of different initiatives to reduce
system delay in the UK. However, a fast-track approach
based on a GP’s suspicion of cancer may not necessarily
be effective as only some 50% of patients present to their
GP with alarm symptoms [26,31]. The effect of seeing
cancer as an acute disease and thereby circumventing
administrative and capacity-driven bottlenecks in the
pathway should be investigated. The fast-track approach
was adopted in Denmark in 2008 [1,27], but it is too
early to evaluate if this initiative has reduced system-
related delay.
Further research is required to test whether improved
access to diagnostic investigations and intra- and inter-
sectoral cooperation within the health care sector will
have an effect on the diagnosis of cancer.
Further analysis of the long delays characterising the
4
th quartile of patients requires clarification of the speci-
fic patient, GP and system characteristics that prolong
delay. Our investigations invite the conclusion that a
more precise research focus on early diagnosis of cancer
is, indeed, warranted [2].
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Figure 4 Total, patient, GP and system delay. Delay (in days) for each patient is shown in the figures.
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Page 7 of 8Conclusions
This study showed that patient and system delay account
for most of the delay in cancer diagnosis. For all compo-
nents of delay, special focus should be given to the 4
th
quartile of the patients. Cancer prognosis may be
improved if we focus on early diagnosis and improved
clinical pathways.
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